Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients

키워드

참고문헌 (84)

1. Koethe JR, "HIV and antiretroviral therapy-related fat alterations", Nat Rev Dis Primers, 6, pp.48~ (2020)
2. Huang PL, "A comprehensive definition for metabolic syndrome", Dis Model Mech, 2, pp.231~237 (2009)
3. Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
4. 김보연, "2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 30(2), pp.81~92 (2021), 대한비만학회[DOI]
5. Nguyen KA, "A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population", PLoS One, 11, pp.e0150970~ (2016)
6. Todowede OO, "Prevalence of metabolic syndrome, discrete or comorbid diabetes and hypertension in sub-Saharan Africa among people living with HIV versus HIV-negative populations : a systematic review and meta-analysis protocol", BMJ Open, 7, pp.e016602~ (2017)
7. Bailin SS, "Obesity and weight gain in persons with HIV", Curr HIV, 2020, pp.17, 138~150
8. Crum-Cianflone N, "Increasing rates of obesity among HIV-infected persons during the HIV epidemic", PLoS One, 5, pp.e10106~ (2010)
9. Tate T, "HIV infection and obesity : where did all the wasting go?", Antivir Ther, 17, pp.1281~1289 (2012)
10. Koethe JR, "Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada", AIDS Res Hum Retroviruses, 32, pp.50~58 (2016)
11. Hasse B, "Obesity trends and body mass index changes after starting antiretroviral treatment : The Swiss HIV cohort study", Open Forum Infect Dis, 1, pp.ofu040~ (2014)
12. Erlandson KM, "A randomized comparison of anthropomorphic changes with preferred and alternative efavirenz-based antiretroviral regimens in diverse multinational settings", Open Forum Infect Dis, 2, pp.ofv095~ (2015)
13. Ilozue C, "Obesity in the HIV-infected population in Northeast England : a particular issue in Black-African women", Int J STD AIDS, 28, pp.284~289 (2017)
14. Taramasso L, "Metabolic syndrome and body weight in people living with HIV infection : analysis of differences observed in three different cohort studies over a decade", HIV Med, 23, pp.70~79 (2022)
15. Han WM, "Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV", HIV Med, 23, pp.274~286 (2022)
16. Bakal DR, "Obesity following ART initiation is common and influenced by both traditional and HIV-", ART-specific risk factors, 2018, pp.73, 2177~2185
17. Bares SH, "HIV-infected women gain more weight than HIVinfected men following the initiation of antiretroviral therapy", J Womens Health(Larchmt), 27, pp.1162~1169 (2018)
18. Phalane E, "The metabolic syndrome and renal function in an African cohort infected with human immunodeficiency virus", South Afr J HIV Med, 19, pp.813~ (2018)
19. Rogalska-Płońska M, "Metabolic syndrome in HIV infected adults in Poland", Kardiol Pol, 76, pp.548~553 (2018)
20. Sears S, "Metabolic syndrome among people living with HIV receiving medical care in Southern United States : Prevalence and risk factors", AIDS Behav, 23, pp.2916~2925 (2019)
21. 오동현, "Metabolic Complications among Korean Patients with HIV Infection: The Korea HIV", AIDS Cohort Study, 2017, pp.32(8), 1268~1274[DOI]
22. Grunfeld C, "Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome", J Clin Endocrinol Metab, 74, pp.1045~1052 (1992)
23. El-Sadr WM, "Effects of HIV disease on lipid, glucose and insulin levels : results from a large antiretroviral-naive cohort", HIV Med, 6, pp.114~121 (2005)
24. Funderburg NT, "Lipid abnormalities and inflammation in HIV inflection", Curr HIV, 2016, pp.13, 218~225
25. Sapuła M, "Impact of combined antiretroviral therapy on metabolic syndrome components in adult people living with HIV : A literature review", Viruses, 14, pp.122~ (2022)
26. Bijker R, "Cardiovascular disease and cardiovascular disease risk in HIV-positive populations in the Asian region", Open AIDS J, 11, pp.52~66 (2017)
27. Lo J, "Dyslipidemia and lipid management in HIV-infected patients", Curr Opin Endocrinol Diabetes Obes, 18, pp.144~147 (2011)
28. Crane HM, "Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care", AIDS, 25, pp.185~195 (2011)
29. Valantin MA, "Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients", J Antimicrob Chemother, 65, pp.556~561 (2010)
30. Plum PE, "Impact of switch from tenofovir disoproxil fumaratebased regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV", BMC Infect Dis, 21, pp.910~ (2021)
31. Lagoutte-Renosi J, "Real-life impact on lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected patients", Curr HIV Res, 19, pp.84~89 (2021)
32. The RESPOND Study Group, "Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents", AIDS, 35, pp.869~882 (2021)
33. Saumoy M, "Do all integrase strand transfer inhibitors have the same lipid profile? review of randomised controlled trials in naïve and switch scenarios in HIV-infected patients", J Clin Med, 10, pp.3456~ (2021)
34. Macallan DC, "Energy expenditure and wasting in human immunodeficiency virus infection", N Engl J Med, 333, pp.83~88 (1995)
35. Macallan DC, "Wasting in HIV infection and AIDS", J Nutr, 129(1S Suppl), pp.238S~242S (1999)
36. Guaraldi G, "The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection", HIV Med, 15, pp.587~594 (2014)
37. McComsey GA, "Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofoviremtricitabine with atazanavir-ritonavir or efavirenz : ACTG Study A5224s", Clin Infect Dis, 53, pp.185~196 (2011)
38. McComsey GA, "Body composition changes after initiation of raltegravir or protease inhibitors : ACTG A5260s", Clin Infect Dis, 62, pp.853~862 (2016)
39. Chen D, "Clinical review 153 : Lipodystrophy in human immunodeficiency virus-infected patients", J Clin Endocrinol Metab, 87, pp.4845~4856 (2002)
40. Kerchberger AM, "Weight gain associated with integrase stand transfer inhibitor use in women", Clin Infect Dis, 71, pp.593~600 (2020)
41. Calmy A, "Dolutegravirbased and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection(NAMSAL) : week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon", Lancet HIV, 7, pp.e677~e687 (2020)
42. Venter WDF, "Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection(ADVANCE) : week 96 results from a randomised, phase 3, non-inferiority trial", Lancet HIV, 7, pp.e666~e676 (2020)
43. Sax PE, "Weight gain following initiation of antiretroviral therapy : Risk factors in randomized comparative clinical trials", Clin Infect Dis, 71, pp.1379~1389 (2020)
44. Surial B, "Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: A cohort study", Ann Intern Med, 174, pp.758~767 (2021)
45. Diggins CE, "Metabolic consequences of antiretroviral therapy", Curr HIV, 2022, pp.19, 141~153
46. Kuo PH, "Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir", cobicistat, tenofovir alafenamide, pp.Int J Infect Dis, 2020[DOI]
47. Ando N, "Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus", Int J Infect Dis, 110, pp.21~28 (2021)
48. Mulenga LB, "Dolutegravir with recycled nRTIs is noninferior to PI-based ART: VISEND trial", CROI Abstract 135. Conference on Retroviruses and Opportunistic Infections (2022)
49. "A working group of the office of AIDS research advisory council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
50. Eckard AR, "Weight gain and integrase inhibitors", Curr Opin Infect Dis, 33, pp.10~19 (2020)
51. Gorwood J, "The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in Human", Simian adipose tissue and human adipocytes, 2020, pp.71, e549~e560
52. Pickering R, "In vitro model to assess antiretroviral therapy on adipocyte biology", CROI Abstract 514. Conference on Retroviruses and Opportunistic Infections (2021)
53. Achhra AC, "Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study", HIV Med, 17, pp.255~268 (2016)
54. Herrin M, "Weight gain and incident diabetes among HIVinfected veterans initiating antiretroviral therapy compared with uninfected individuals", J Acquir Immune Defic Syndr, 73, pp.228~236 (2016)
55. Yuh B, "Weight change after antiretroviral therapy and mortality", Clin Infect Dis, 60, pp.1852~1859 (2015)
56. Achhra AC, "Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals : D : A : D cohort analysis", J Acquir Immune Defic Syndr, 78, pp.579~588 (2018)
57. Nansseu JR, "Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy : A systematic review and meta-analysis", Epidemiology, 29, pp.431~441 (2018)
58. Butt AA, "HIV infection and the risk of diabetes mellitus", AIDS, 23, pp.1227~1234 (2009)
59. Duncan AD, "Type 2 diabetes prevalence and its risk factors in HIV : A cross-sectional study", PLoS One, 13, pp.e0194199~ (2018)
60. Putcharoen O, "New-onset diabetes in HIV-treated adults : predictors, long-term renal and cardiovascular outcomes", AIDS, 31, pp.1535~1543 (2017)
61. Brown TT, "Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study", Arch Intern Med, 165, pp.1179~1184 (2005)
62. Kim JH, "Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls : A nationwide population-based study in South Korea", HIV Med, 22, pp.824~833 (2021)
63. Shah ASV, "Global burden of atherosclerotic cardiovascular disease in people living with HIV : Systematic review and meta-analysis", Circulation, 138, pp.1100~1112 (2018)
64. Triant VA, "Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease", J Clin Endocrinol Metab, 92, pp.2506~2512 (2007)
65. Sattler FR, "Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation", J Acquir Immune Defic Syndr, 68, pp.281~288 (2015)
66. Yu B, "Metabolic syndrome and neurocognitive deficits in HIV infection", J Acquir Immune Defic Syndr, 81, pp.95~101 (2019)
67. McCutchan JA, "Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder", Neurology, 78, pp.485~492 (2012)
68. Demir M, "Nonalcoholic fatty liver disease-current status and future directions", J Dig Dis, 16, pp.541~557 (2015)
69. Younossi ZM, "Non-alcoholic fatty liver disease-A global public health perspective", J Hepatol, 70, pp.531~544 (2019)
70. Cervo A, "NASH in HIV", Curr HIV, 2020, pp.17, 601~614
71. Benmassaoud A, "Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection", PLoS One, 13, pp.e0191985~ (2018)
72. Maurice JB, "Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection", AIDS, 31, pp.1621~1632 (2017)
73. Cefalu WT, "Advances in the science, treatment, and prevention of the disease of obesity : Reflections from a diabetes care editors’ expert forum", Diabetes Care, 38, pp.1567~1582 (2015)
74. Engelson ES, "Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women", Metabolism, 55, pp.1327~1336 (2006)
75. Fitch KV, "Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome", AIDS, 20, pp.1843~1850 (2006)
76. Reeds DN, "HIV infection does not prevent the metabolic benefits of diet-induced weight loss in women with obesity", Obesity(Silver Spring), 25, pp.682~688 (2017)
77. Gjermeni E, "Obesity-an update on the basic pathophysiology and review of recent therapeutic advances", Biomolecules, 11, pp.1426~ (2021)
78. Cope RJ, "Safety and efficacy of weight-loss pharmacotherapy in persons living with HIV : A review of the literature and potential drug-drug interactions with antiretroviral therapy", Pharmacotherapy, 39, pp.1204~1215 (2019)
79. Akbari K, "The effect of bariatric surgery on patients with HIV infection : a literature review", Obes Surg, 28, pp.2550~2559 (2018)
80. Selke H, "Bariatric surgery outcomes in HIVinfected subjects : a case series", AIDS Patient Care STDS, 24, pp.545~550 (2010)
81. Pourcher G, "Bariatric surgery in HIV patients : experience of an obesity reference center in France", Surg Obes Relat Dis, 13, pp.1990~1996 (2017)
82. Sharma G, "Comparative outcomes of bariatric surgery in patients with and without human immunodeficiency virus", Obes Surg, 28, pp.1070~1079 (2018)
83. Sharma P, "Impact of bariatric surgery in patients with HIV infection : a nationwide inpatient sample analysis, 2004-2014", AIDS, 32, pp.1959~1965 (2018)
84. Amouyal C, "Sleeve gastrectomy in morbidly obese HIV patients : Focus on anti-retroviral treatment absorption after surgery", Obes Surg, 28, pp.2886~2893 (2018)

관련 논문AI추천